Rogister B
Centre de Neurobiologie cellulaire et moléculaire, et Service de Neurologie, U.Lg.
Bull Mem Acad R Med Belg. 2003;158(5-6):227-35; discussion 235-7.
For several years, in Parkinson's disease patients, immature neuroblasts grafts could be realized. Those immature cells come from mesencephalic regions of six to ten weeks-old embryos. Given several technical problems, clinical outcome of the patients is not favourable and moreover, it appears that the cell source is very limited. That's the reason why the use of embryonic or somatic stem cells could be promising. Stem cells are able to self-renew, and could differentiate into several cell types. In this lecture, the author reviews the biological properties of different stem cells types in order to be used in cerebral graft in several neurological diseases. Given their recently unravelled phenotypic plasticity, somatic stem cells could be the best candidate for such a clinical use for autografts.
几年来，在帕金森病患者中，可以进行未成熟神经母细胞移植。这些未成熟细胞来自6至10周龄胚胎的中脑区域。由于存在一些技术问题，患者的临床结果并不理想，而且细胞来源似乎非常有限。这就是为什么使用胚胎干细胞或成体干细胞可能很有前景的原因。干细胞能够自我更新，并可分化为多种细胞类型。在本次讲座中，作者回顾了不同类型干细胞的生物学特性，以便用于治疗几种神经疾病的脑移植。鉴于其最近发现的表型可塑性，成体干细胞可能是自体移植这种临床应用的最佳候选者。
